Phase I/II trial of external irradiation plus medium-dose brachytherapy given concurrently to liposomal doxorubicin and cisplatin for advanced uterine cervix carcinoma

Strahlentherapie und Onkologie

Volumn 182, Issue 3, 2006, Pages 125-134

  Varveris, Haralambos ^a,d   Kachris, Stefanos ^a   Mazonakis, Michael ^a   Lyraraki, Efrossini ^a   Petineli, Effie ^a   Varveris, Antonios ^a   Fasoulaki, Anastasia ^a   Tzedakis, Antonios ^a   Kouloulias, Vasilis ^b   Zolindaki, Angeliki ^a   Vlachaki, Maria ^c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Iraclion University Hospital   (Greece)

Author keywords

Cervical cancer; Cisplatin; Liposomal doxorubicin; Radiotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HOT FLUSH; HUMAN; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PARAAORTIC LYMPH NODE; PATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCTITIS; RADIATION DOSE; RASH; RECTUM HEMORRHAGE; SKIN EXFOLIATION; SKIN TOXICITY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; CANCER INVASION; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; SURVIVAL; UTERUS CANCER;

ADULT; AGED; BRACHYTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOTHERAPY; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 33646087684     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1440-0     Document Type: Article

References (50)

1. Almarie U, Bernardo LR, Rabia M. Phase I trial of pegylated-liposomal doxorubicin (Caelyx, Doxil) and carboplatin in patients with advanced malignancies. Proc Am Soc Clin Oncol 2002;21:abstract 2138.
2. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Oncol Biol Phys 1990;57:55-64.
3. Braud AC, Goncalves A, Genre D, et al. Phase I study of liposomal doxorubicin (Caelyx) in combination with carboplatin (CBDCA) in patients with advanced or metastatic solid tumors. Proc Am Soc Clin Oncol 2001;20: abstract 2113.
4. Chauvergne J, Lhomme C, Rohart J, et al. Neoadjuvant chemotherapy of stage IIb and III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients. Bull Cancer 1993;80:1069-79.
5. Disilvestro PA, Fisher M, Pearl M, et al. Phase II trial of pegylated liposomal doxorubicin as consolidation chemotherapy in patients with stage III or IV ovarian or primary peritoneal carcinoma. Proc Am Soc Clin Oncol 2004;22: abstract 5112.
6. Dunst J, Haensgen G. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy. Strahlenther Onkol 2001;177:635-40.
7. Girinsky T, Rey A, Roche B, et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-6.
8. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-6.
9. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabelled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
10. Harrington KJ, Rowlinson-Busza G, Uster PS, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumors. Cancer Chemother Pharmacol 2000;46:10-8.
11. Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000;78:143-7.
12. Jacobs R, Mauer A, Fleming G, et al. Phase I study of Doxil (DOX), paclitaxel (TAX) and cisplatin (CIS) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2000;19:abstract 1609.
13. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
14. John MJ. Grading of chemoradiation toxicity. In: Yohn MJ, Flam MS, Legha S, eds. Chemoradiation: an integrated approach to cancer treatment. Philadelphia: Lea & Febiger; 1993:601-6.
15. Kavanagh J, Verschraegen C, Levenback C, et al. A phase II study to evaluate the efficacy and toxicity of carboplatin plus Doxil administered intravenously as a single infusion every 28 days to women with advanced or recurrent squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 2000;19: abstract 1561.
16. 2) in the treatment of gynecologic cancers. Proc Am Soc Clin Oncol 2004;22:abstract 5080.
17. Koumantakis E, Haralambakis Z, Koukourakis M, et al. A pilot study on concurrent platinum chemotherapy and intracavitary brachytherapy for locally advanced cancer of the uterine cervix. Br J Radiol 1998;71:552-7.
18. Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391-7.
19. Le LH, Swenerton KD, Elit D, et al. Phase II open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Proc Am Soc Clin Oncol 2003;22:abstract 1839.
20. Lehman M, Thomas G. Is concurrent chemotherapy and brachytherapy the new standard of care for locally advanced cervical cancer? Int J Gynecol Cancer 2001;11:87-99.
21. Lopez F, Sikov W. Phase I studies of weekly docetaxel with Doxil or weekly doxorubicin. Proc Am Soc Clin Oncol 2000;19:abstract 830.
22. Manji M, Raja MA, Kerr I, et al. Concurrent chemoradiation therapy (CCRT) with weekly cisplatin in locally advanced cancer cervix (LACC): single institution experience. Proc Am Soc Clin Oncol 2004;22:abstract 5107.
23. B cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol 2004;180:209-25.
24. Mitsuhashi A, Uno T, Tanaka N, et al. Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Proc Am Soc Clin Oncol 2004;22:abstract 5103.
25. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation and concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
26. Muggia F, Hornreich G, Wadler S, et al. Overview of toxicities from a combination of Doxil-paclitaxel in a New York Gynecologic Oncology Group (NYGOG) study on endometrial carcinoma and sarcomas. Proc Am Soc Clin Oncol 1999;18:abstract 1469.
27. Muggia F, Kim E, Downey A, et al. Safety of prolonged Doxil administration in recurrent gynecologic cancers. Proc Am Soc Clin Oncol 2004;22: abstract 5055.
28. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-72.
29. Perez CA, Kuske RR, Camel HM, et al. Analysis of pelvic tumor control and impact on survival in carcinoma of the uterine cervix treated with radiation therapy alone. Int J Radiat Oncol Biol Phys 1988;14:613-21.
30. Peter CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;30:1275-88.
31. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci 1995;20:156-60.
32. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
33. Russell AH, Shingleton HM, Jones WB, et al. Trends in the use of radiation and chemotherapy in the initial management of patients with carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1998;40:605-13.
34. Serkies K. J. Jassem on A. Mayer, et al. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol 2004;180:209-15.
35. B carcinoma of the cervix. J Clin Oncol 1991;9:970-7.
36. Souhami L, Seymour R, Roman TN, et al. Weekly cisplatin plus external beam radiotherapy and high dose brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993;27:871-8.
37. Stewart S, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 1997;11:533-7.
38. Strauss HG, Kuhnt T, Laban C, et al. Chemoradiation in cervical cancer with cisplatin and high dose brachytherapy combined with external beam radiotherapy. Results of a phase II study. Strahlenther Onkol 2002;178:378-85.
39. Symonds R, Habeshaw A, Reed N, et al. The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. Eur J Cancer 2000;36:994-1001.
40. Tacev T, Vacek A, Plackova B, et al. Hypoxic versus normoxic external-beam irradiation of cervical carcinoma combined with californium-252 neutron brachytherapy comparative treatment. Results of a 5-year randomized trial. Strahlenther Onkol 2005;181:273-84.
41. Tattersall MH, Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 1995;13:444-51.
42. Toita T, Moromizato H, Ogawa K, et al. Concurrent chemoradiotherapy using high dose rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 2005;96:665-70.
43. Varveris H, Kachris S, Mazonakis M, et al. Pegylated liposomal doxorubicin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung. Oncol Rep 2004;12:473-81.
44. Varveris H, Mazonakis M, Lyraraki E, et al. A pilot study of preoperative (MDR brachytherapy ± external irradiation) given concurrently to Caelyx and CDDP for endometrial carcinoma. Radiother Oncol 2000;56 (Suppl 1):S70.
45. Varveris H, Mazonakis M, Vlachaki M, et al. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of the head and neck. Oncol Rep 2003;10:185-95.
46. A carcinoma of the cervix with negative para-aortic nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
47. Windschall A, Ott OS, Sauer R, et al. Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma. Strahlenther Onkol 2005;181:545-50.
48. Wong LC, Choo YC, Choy D, et al. Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 1989;35:159-63.
49. Wong LC, Ngan HY, Cheung AN, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17:2055-60.
50. Wulf J, Popp K, Oppitz U, et al. Positional variability of a tandem applicator system in HDR brachytherapy for primary treatment of cervix cancer. Analysis of the anatomic pelvic position and comparison of the applicator positions during five insertions. Strahlenther Onkol 2004;180:216-24.